Because MHC-1 antigen presentation deficiency is a common cancer immune escape mechanism, combining tumor-targeting antibodies with IL-2 mRNA restored CD8+ T cell neoantigen immunity in MHC class I-deficient tumors that were otherwise resistant to immune-, chemo-, and radiotherapy (166). This evidence concerns the gene CD8A and cancer.